Estimation of the Prevalence of Microcirculatory Dysfunction in Uremic Cardiopathy Among Dialysis Patients

NCT07608679 | Not Yet Recruiting

• 1 other identifier: CHD24_0002
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with end-stage renal disease have a high burden of cardiovascular mortality, yet ischemic heart disease is often asymptomatic and difficult to diagnose in this population. Recent data suggest that microvascular coronary dysfunction may contribute significantly to myocardial ischemia in dialysis patients, but its true prevalence remains unknown. This study aims to evaluate microcirculatory coronary impairment in hemodialysis patients using invasive coronary angiography with measurement of coronary flow reserve (CFR), index of microcirculatory resistance (IMR). The study will also describe the clinical and biological characteristics associated with microvascular dysfunction in this population, in order to better understand the mechanisms of uremic cardiomyopathy and improve cardiovascular risk stratification.

Conditions

Hemodyalysis

Keywords

microcirculatory disorders; hemodyalysis

Outcome Measures

Primary Outcomes (1)

• Percentage of patients with microcirculatory heart disease (i.e. microvascular dysfunction or microvascular vasospasm) identified during coronary angiography

  Cardiac examinations to be carried out within 8 to 10 weeks of enrolment

Interventions

Transthoracic ultrasound at rest DIAGNOSTIC_TEST

Transthoracic ultrasound at rest

Cardiological stress test DIAGNOSTIC_TEST

Left to the discretion of the centre: dobutamine echocardiography or myocardial scintigraphy.

Coronary angiography DIAGNOSTIC_TEST

Even even if the stress test comes back normal (these tests appear to be less effective at diagnosing microcirculatory abnormalities)

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years
• Patients who have been on haemodialysis for at least 6 months
• Elevated troponin levels \> 40 ng/L in a sample taken whilst the patient was in a stable condition, dated within the last 3 months
• Patients capable of understanding the protocol and who have given their written informed consent to participate in the research
• Patients registered with the National Health Service or eligible for it

You may not qualify if:

• Age \> 90 years
• Patient undergoing daily home haemodialysis
• Symptomatic stage 3 or 4 peripheral arterial disease
• Severe hypertrophic cardiomyopathy (genetic or amyloid)
• Severe valvular heart disease leading to left ventricular remodelling (surgically contraindicated severe aortic stenosis, severe mitral regurgitation, severe aortic regurgitation)
• Hospitalisation for decompensation/acute heart failure within the last month
• Acute coronary syndrome and any coronary artery disease requiring angioplasty and/or stent implantation within the last 3 months
• Contraindication to METHERGIN and DOBUTAMINE
• Patients participating in another clinical research protocol that may affect the research objectives
• Patients already included in the study
• Patients under guardianship, curatorship or deprived of their liberty
• Patients under an activated future protection order
• Patients under family authorisation
• Patient under judicial protection
• Pregnant patient

Sponsors & Collaborators

• Centre Hospitalier Departemental Vendee: lead

Study Sites (1)

Centre Hospitalier Départemental Vendée

La Roche-sur-Yon, 85000, France

Location

MeSH Terms

Interventions

Coronary Angiography

Intervention Hierarchy (Ancestors)

Cardiac Imaging Techniques; Diagnostic Imaging; Diagnostic Techniques and Procedures; Diagnosis; Angiography; Radiography; Diagnostic Techniques, Cardiovascular; Heart Function Tests

Study Officials

• Grégoire COUVRAT-DESVERGNES

  Centre Hospitalier Departemental Vendee

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Chloé MOREAU

CONTACT

251446327; promotion.urc@chd-vendee.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 20, 2026
• First Posted: May 27, 2026
• Study Start (Estimated): September 1, 2027
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): September 1, 2028
• Last Updated: May 27, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)